Josh Disbrow

About Me

Josh Disbrow, a resident of Denver, CO, stands as a distinguished luminary within the pharmaceutical industry, boasting an extensive and diverse quarter-century experience spanning pharmaceuticals, diagnostics, and medical devices. His professional journey is marked by the triumphant founding and establishment of Aytu BioPharma, which has flourished remarkably under his guidance, alongside noteworthy contributions to other prominent pharmaceutical entities. Beyond his professional accomplishments, Josh's persona is illuminated by his deep-rooted familial ties, musical inclinations, and genuine commitment to philanthropy. Josh steers the ship with visionary leadership as the Chief Executive Officer and Board Director of Aytu BioPharma, a company he co-founded in 2015. Under his guidance, Aytu BioPharma achieved a significant milestone by securing a listing on NASDAQ in 2017, surpassing $100 million in annual revenues within seven years. His strategic prowess is further showcased through the orchestration of four company acquisitions in under four years, solidifying the company's growth trajectory.

Furthermore, as a Director at Zynex, Inc., a publicly-listed medical device firm specializing in electrotherapy and pain management, Josh assumes a leadership role as a board member. His commitment to corporate governance is exemplified through his Nominating and Governance Committee chairmanship. Josh's career journey commenced as a sales representative at Glaxo Wellcome (now GlaxoSmithKline plc). His upward trajectory led him to pivotal roles in commercial and leadership capacities at esteemed institutions such as Cyberonics, LipoScience, Arbor Pharmaceuticals, and Ampio Pharmaceuticals. An apex of his career was his transformative role at Arbor, where he catalyzed the company's evolution from pre-commercialization to amassing over $250 million in revenue within a remarkable five-year span.